



Meitheal Pharmaceuticals – Recall of cisatracurium injection

- On January 27, 2021, [Meitheal announced](#) a voluntary, user level recall of one lot of [cisatracurium injection](#) because a product complaint revealed that a portion of one lot of cartons labeled as cisatracurium injection 10 mg/5 mL, containing ten vials per carton, contained ten vials mis-labeled as [phenylephrine hydrochloride injection](#) 100 mg/10 mL.
- Meitheal commenced shipping the product on August 19, 2020 which was distributed to wholesalers nationwide in the U.S.:

Product Description	NDC#	Lot# (Expiration Date)
Cisatracurium besylate injection, 10 mg per 5 mL	71288-712-06 (unit of sale); 71288-712-05 (unit of use)	C11507A* (10/2021)

*Note: Mis-labeled product will have this same lot number of C11507A and expiration date of 10/2021 but will be labeled on the vial as phenylephrine hydrochloride injection.

- Cisatracurium injection is indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age; to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the intensive care unit; and to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older.
- There is a reasonable probability that a patient who requires cisatracurium for muscle paralysis as part of general anesthesia is administered phenylephrine instead would not receive any skeletal muscle relaxation and could cause a hyperadrenergic state resulting in elevated blood pressure, arrhythmia and cardiac/brain ischemia. If this is not quickly diagnosed and treated, severe illness or death can occur.
- There is a reasonable probability that a patient who requires phenylephrine to increase their blood pressure, such as patients with severely low blood pressure, especially resulting from septic shock who is administered cisatracurium instead could result in a fast onset of muscle paralysis and decrease in oxygen. If this is not quickly diagnosed and treated, severe illness or death can occur within minutes.
- To date, Meitheal has not received reports of any adverse events or identifiable safety concerns attributed to the recalled lot.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the recalled cisatracurium injection.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact Meitheal at **1-844-824-8426** for further information regarding this recall.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.